HCAT vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HCAT exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic 5-year price decline of 98%. While the stock appears cheap on a Price-to-Book (0.29) and Price-to-Sales (0.24) basis, these are 'value traps' given the negative revenue growth (-6.20%) and a massive collapse in YoY EPS (-3300%). The technical trend is completely bearish (0/100), and insider activity is negative, suggesting a lack of confidence from company leadership.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HCAT vs LLY: Head-to-Head Comparison
This page compares Health Catalyst, Inc. (HCAT) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.